MedTrace Logo

Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping

NCT06561022 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2024-08-19

No results posted yet for this study

Summary

To explore the efficacy and safety of Everolimus (SNF1 subtype) or Fluzoparib (SNF3 subtype) combined with Fulvestrant and Abemaciclib vs. Fulvestrant combined with Abemaciclib in patients with HR+/HER2- breast cancer of SNF1/SNF3 subtype who have progressed after CDK 4/6 inhibitor treatment.

Conditions

Interventions

DRUG

Fluzoparib

Fluzoparib

DRUG

Everolimus

Everolimus

DRUG

Fulvestrant

Fulvestrant

DRUG

Abemaciclib

Abemaciclib

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Zhimin C Shao, MD, PhD · Fudan U

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-21
Primary Completion
2025-12-31
Completion
2026-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06561022 on ClinicalTrials.gov